Perspectives for the Clinical Use of Aromatase Inhibitors

摘要: The enzyme aromatase catalyzes the rate-limiting step in estrogen biosynthesis both men and women. availability of more potent, selective non-toxic inhibitors could potentially provide effective therapy for a number estrogen-dependent diseases. Clinical application these agents depends upon physiologic source ability regulatory systems to counteract effects inhibitors. Consequently, blockade might be postmenopausal women than premenopausal or men. In assessing inhibitors, various advantages disadvantages all available strategies block synthesis action must considered. Such analysis suggests that will find an important place management breast endometrial carcinomas possibly benign diseases such as endometriosis, leiomyomata uteri, perimenopausal bleeding gynecomastia.